Personal Finance

Why Pieris Pharmaceuticals Inc. Is Soaring Today

Two businessmen looking over a contract

What happened

In response to the company's new collaboration deal, shares of Pieris Pharmaceuticals (NASDAQ: PIRS) , a clinical-stage biotech focused on cancer and other diseases, jumped as much as 16% in early morning trading on Friday. As of 12:15 p.m. EST, the stock was up 9%.

So what

Pieris Pharmaceuticals stated that it has signed a new collaboration deal with Seattle Genetics (NASDAQ: SGEN) , a biotechnology company that is also focused on cancer. The aim of this new partnership is to leverage both companies' expertise and technology to develop new immuno-oncology treatments for solid tumors and blood cancers.

This deal provides Pieris with an up-front payment of $30 million and the ability to earn up to $1.2 billion in milestone payments, plus double-digit royalties on any potential product sales.

Two businessmen looking over a contract

Image source: Getty Images.

While the companies will produce multiple compounds together, Seattle Genetics retains the option to select up to three products for further development. What's more, if the companies get to the pivotal-trial stage with a compound, then Pieris has the option to pick one compound and can share in global costs and profits on a 50-50 basis.

This deal represents yet another vote of confidence for Pieris' technology, so it's easy to understand why investors are bidding up shares today.

Now what

Pieris has a knack for getting deep-pocketed biopharma companies to help fund its growth. Last year, it successfully signed lucrative deals that featured up-front payments with a French pharma company called Servier and pharma giant AstraZeneca . In prior years, the company also earned payments from the likes of Allergan , Sanofi , Roche , and Daiichi Sankyo.

My ears always perk up when I see a small-cap biotech with an interesting technology that grabs the attention of the industry giants. Today's announcement only enhances my interest in this company's future so I plan to follow Pieris' progress with great interest from here on out.

10 stocks we like better than Piers Pharmaceuticals

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Piers Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of February 5, 2018

Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool recommends Seattle Genetics. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

SGEN PIRS

Other Topics

Stocks

Latest Personal Finance Videos

How Student Loan Refinancing Works

Though it may be a great way to lower monthly payments, not everyone understands the student loan refinancing process. NerdWallet explains it. For more, try our refinance calculator: http://bit.ly/nerdwallet-student-loan-refinancing-calculator

Nov 25, 2019

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More